TAMPA, Fla. (October 17, 2018) – Today, Leone Asset Management (OTC PINK: LEON) announced their subsidiary Go Epic Health is conducting additional case studies and clinical research on their all-natural cholesterol-lowering product Cholesterade®.
James Price, CEO of Go Epic Health, stated, “With heart disease being the largest killer in the country, we hope that the use of this all-natural product in America’s daily diet will have a major impact on the heart health of our nation and in the world. These additional studies will help to prove not only short-term results but the long-term benefits of Cholesterade® across demographics.”
The first of the new studies will be completed by Center of Prevention and Wellness in Memphis, Tennessee and has been filed with WIRB (study number 1188721). This is a multi-center double-blind study to test the lipid-lowering effects and cardiovascular benefits of the product on a long-term basis with quarterly results being published.
The second study will be conducted at The Cardiac and Vascular Institute Research Foundation, under the direct supervision of Chris Caputo, M.D. in Gainesville, Florida. This short-term 90-day study will test the lipid-lowering effects and cardiovascular benefits of the product within a post-cardiac event group.
The last study will be conducted by Nitza Alvarez, M.D. at the Tri-County Heart Institute in The Villages, Florida. This study will include a large group of female-only participants and will also be a short-term 90-day study with a more advanced, in-depth look into a lipid panel to include the efficacy of Cholesterade® on LDL particles within the blood, as well as other markers.
Recently, Go Epic Health partnered with Richard Goldfarb, M.D. to complete a new proof of concept study. Before the study, minor improvements were made to the original formula of the product, by adding a specific and proprietary enzyme blend as well as an all-natural and patent-pending delivery system to improve the efficacy of the product. He found improved results, due to the enhanced formula, throughout an eight week period. Participants saw a reduction in bad cholesterol or LDL of 25 percent and an increase in good cholesterol or HDL of 13 percent and a reduction in Triglycerides of 53 percent.
Cholesterade® was initially created by the late J. Robert Cade, M.D., the inventor of Gatorade®, to lower his cholesterol levels. Cade was taking statin drugs for the problem but suffered from significant side effects from the use. Therefore, he decided to create an all-natural alternative.
Once established, Dr. Cade performed an initial case study and found the results to be remarkable. Without making any other lifestyle changes, study participants saw a reduction in triglycerides of 50 percent a reduction of bad cholesterol or LDL of 21.3 percent; and a rise of good cholesterol or HDL of 12.9 percent in an eight week period.
Price said, “We believe at the conclusion of these studies, the new and published data will create a tremendous amount of additional educational and proven data for the world to know the efficacy and the benefits of Cholesterade® on naturally lowering cholesterol.”
About Leone Asset Management:
Leone Asset Management, Inc., is a multi-national, multi-industry conglomerate with subsidiary companies that operate in Health and Wellness, Infrastructure development and agriculture management. For additional information, visit www.leoneasset.com.
About Go Epic Health:
Go Epic Health, a Leone Asset Management subsidiary, is a nutritional product holding company which owns the intellectual property and worldwide manufacturing and distribution rights to Cholesterade®, a natural cholesterol reducing product created by the late Robert Cade, M.D., creator of Gatorade®. Go Epic Health markets and distributes Cholesterade® as well as other new and innovative consumer goods through the retail pharmacy chain stores, drug and health food stores and product-specific catalogs. For further information, please visit www.goepichealth.com and www.cholesterade.com.